{"filings":[{"id":452876,"accession_number":"0001493152-26-023367","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-05-15T12:20:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q1 net loss $1.2M, cash $3.3M; merger with Eos SENOLYTIX set for Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.172M ($0.32/share) vs $1.808M ($0.50/share) in Q1 2025; no revenue reported.","Cash and equivalents $3.3M at March 31, 2026; going concern assumed through anticipated merger close.","Merger agreement with Eos SENOLYTIX signed March 26, 2026; expected close Q3 2026; common stock holders get ~6% of combined co.","Private placement of Series B convertible preferred stock from Eos affiliate raised $1.0M gross in March.","R&D expense <$0.1M; G&A down to $1.3M from $1.8M; clinical programs on hold pending out-license."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93782,"accession_number":"0001493152-26-018202","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix closes $1M Series B preferred placement as part of planned merger with Eos","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Gross proceeds of approximately $1 million from Series B Preferred Stock issued to Eos affiliate.","Conversion price of $2.20 per share; convertible 90 days after issuance.","Placement is an initial step in the planned merger with Eos SENOLYTIX; definitive agreement signed.","Net proceeds to be used for working capital and general corporate purposes.","Interim CEO Peter Ludlum highlighted the investment as part of the ongoing merger process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105690,"accession_number":"0001493152-26-013266","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","3.02","3.03","5.01","5.03","7.01","9.01"],"status":"ready","headline":"Pulmatrix to merge with Eos SENOLYTIX; Eos stockholders to own ~94% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-Merger Eos stockholders to own ~94% of combined company; Pulmatrix stockholders ~6% on fully-diluted basis.","Combined company to be renamed 'Eos SENOLYTIX, Inc.'; board of 6 members, 5 designated by Eos.","Pulmatrix raises $1M via Series B Convertible Preferred (8% dividend, conversion at $2.20) from Eos affiliate.","Eos to raise up to $18M via convertible notes (8% interest) and Series A Preferred financing.","Closing conditions include stockholder approvals, Nasdaq listing, and SEC registration statement effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105689,"accession_number":"0001493152-26-008449","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix merger with Cullgen terminated; seeks alternative merger opportunities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cullgen terminated the Merger Agreement on Feb 28, 2026 citing failure to obtain China Securities Regulatory Commission approval.","No termination fee payable by either party; each will bear its own costs and expenses.","Pulmatrix continues pursuing alternative reverse merger opportunities, encouraged by industry activity.","Prior mutual waiver of no-solicitation clause had already allowed each party to explore alternate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105688,"accession_number":"0001493152-26-008129","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix: $0 revenue in 2025, net loss $5.2M, plans to license iSPERSE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0 in 2025 vs $7.8M in 2024; net loss $5.2M ($1.41/share) vs $9.6M.","Cash and equivalents $4.1M at Dec 31, 2025, down from $9.5M; cash runway into Q1 2027.","Plans to license or monetize iSPERSE platform and migraine asset PUR3100.","Proposed merger with Cullgen pending CSRC approval; 'No Solicitation' clause waived to explore alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121970,"accession_number":"0001493152-25-028283","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix and Cullgen waive no-solicitation clause, explore alternatives due to CSRC delay","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Parties mutually waived the 'No Solicitation' clause (Section 5.4) of the Nov 2024 Merger Agreement.","Waiver permits each party to explore alternate transactions while continuing to pursue CSRC merger approval.","CSRC approval remains the primary unmet closing condition; S-4 effective May 2025, stockholder vote June 2025.","Pulmatrix had $4.8M cash as of Sept 30, 2025, funding operations into at least Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121969,"accession_number":"0001493152-25-018252","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.","Pursuing divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900) ahead of proposed Cullgen merger.","Proposed merger with Cullgen stockholder-approved; closing subject to Nasdaq & China regulatory approval.","R&D expenses fell to <$0.1M; G&A down to $0.9M due to winddown and cost cuts.","PUR3100 Phase 2 ready for acute migraine; PUR1900 partner Cipla advancing Phase 3 in India."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138670,"accession_number":"0001641172-25-022354","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports Q2 2025 net loss $1.5M; merger with Cullgen expected 2025; plans divestment of iSPERSE assets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $0 from $1.6M in Q2 2024 due to PUR1900 wind-down; net loss $1.549M ($0.42 per share).","Cash and equivalents $5.825M; company expects funds to last through expected close of proposed Cullgen merger.","Proposed merger with Cullgen approved by stockholders; closing in 2025 subject to Nasdaq and China regulatory approvals.","Pulmatrix intends to divest iSPERSE technology and clinical programs PUR3100, PUR1800, PUR1900 as part of merger.","R&D expenses dropped to $0.1M from $2.8M; G&A decreased to $1.5M from $2.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156123,"accession_number":"0001641172-25-015249","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Pulmatrix stockholders approve merger proposals; CSRC clearance still outstanding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven proposals approved by stockholders at June 16 special meeting, including issuance of shares for Cullgen merger.","Reverse stock split authorized at ratio of 1-for-2 to 1-for-10, with final ratio to be set by board; authorized shares increased to 250M.","Merger remains subject to CSRC approval under China's Trial Measures; Pulmatrix notes CSRC approval not yet received.","Richard Batycky re-elected as Class II director; CBIZ CPAs ratified as auditor for FY2025 (subject to change post-merger).","Proposal 1 (share issuance >20% and change of control) passed with 798,652 votes for, 65,788 against, 2,428 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156122,"accession_number":"0001641172-25-010525","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports Q1 loss; plans asset divestment, Cullgen merger close targeted for June","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 2025 revenue $0 vs $5.9M YoY; net loss $1.8M (-$0.50 EPS) vs net income $0.825M in Q1 2024.","Cash balance $7.7M; expects to fund operations through merger close in June 2025.","Merger with Cullgen anticipated to close in June 2025; registration declared effective by SEC.","Company intends to divest assets including PUR3100 (Phase 2-ready acute migraine candidate) and iSPERSE technology.","R&D expenses decreased to less than $0.1M from $3.5M YoY due to wind-down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156121,"accession_number":"0001641172-25-003620","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["1.01","5.01","9.01"],"status":"ready","headline":"Pulmatrix and Cullgen amend merger agreement to one-step merger; Second Merger Sub removed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment No. 1 dated April 7, 2025 changes transaction from two-step to one-step merger, eliminating Second Merger Sub.","Clarifies fractional shares provision; Cullgen will survive as wholly owned subsidiary of Pulmatrix.","Boards of both companies approved the amendment; all other terms of original November 13, 2024 agreement remain.","Transaction remains subject to stockholder approval, regulatory clearances, and Nasdaq listing; consideration unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156120,"accession_number":"0001641172-25-003216","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Pulmatrix auditor change: Marcum resigns, CBIZ engaged effective April 4, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 4, 2025; no adverse opinions or disagreements in prior reports.","Audit Committee approved engagement of CBIZ CPAs P.C. as new independent auditor for fiscal 2025.","Auditor transition follows CBIZ’s November 2024 acquisition of Marcum’s attest business.","No reportable events or disagreements occurred during 2023, 2024, or interim period through April 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174557,"accession_number":"0001493152-25-011082","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix reports 2024 net loss of $9.6M; proposes merger with Cullgen and asset divestment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2024 of $9.6M ($2.62 per share) vs $14.1M ($3.87 per share) in 2023.","Revenues increased to $7.8M from $7.3M, driven by a contract modification with Cipla.","Cash and equivalents $9.5M; sufficient to fund operations through anticipated Merger close in H1 2025.","Proposed merger with Cullgen expected to close H1 2025; plans to divest Phase 2-ready PUR3100 and iSPERSE technology.","PUR1900 Phase 2b enrollment paused; no further financial responsibility; 2% royalties on future net sales outside U.S."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174556,"accession_number":"0001493152-25-006588","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pulmatrix amends bylaws to revise voting standards language","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Board approved Amendment No. 2 on Feb 11, 2025, effective immediately.","Amendment revises voting standards language in Article I, Section 7 of the Bylaws.","No specific details on the change were disclosed; routine governance update.","No financial or operational impact stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191519,"accession_number":"0001493152-24-050889","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulmatrix stockholders elect two Class I directors, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Todd Bazemore and Christopher Cabell as Class I directors with votes for 285,646 and 334,230, respectively.","Ratified Marcum LLP as independent auditor for FY2024: 1,705,315 for, 47,547 against, 103,282 abstain.","Annual meeting quorum: 1,856,171 shares (50.82% outstanding); broker non-votes on director elections: 1,318,725.","No other proposals were considered or voted upon at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191518,"accession_number":"0001493152-24-044986","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Pulmatrix to merge with Cullgen in reverse merger; Cullgen holders to own 96.4%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pulmatrix to merge with Cullgen; exchange ratio implies Cullgen valuation of $280M, Pulmatrix $10.5M.","Pre-merger Cullgen stockholders to own ~96.4% of combined company; Pulmatrix stockholders ~3.6%.","Pulmatrix plans cash dividend to pre-merger stockholders if net cash exceeds $2.5M at closing.","Combined company board: eight members, seven from Cullgen, one from Pulmatrix.","Closing conditions include stockholder votes, Nasdaq listing, SEC S-4 effectiveness, CSRC approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191517,"accession_number":"0001493152-24-044160","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q3 2024 revenue down 79% YoY to $0.4M; cash runway into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.6M ($0.71 per share) vs $3.8M ($1.03) in Q3 2023.","Revenue fell to $0.4M from $1.8M due to PUR1900 wind down; R&D expenses cut 80% to $0.8M.","Cash and equivalents $10.8M; company expects funding into Q4 2026.","Completed wind down of PUR1900 Phase 2b; no further financial obligation, to receive 2% royalties ex-US.","Closed MannKind cross-license for iSPERSE technology; pursuing strategic alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7803000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191516,"accession_number":"0001493152-24-040453","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Pulmatrix sets 2024 annual meeting for Dec 18; Oct 31 record date","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2024 Annual Meeting scheduled for Wednesday, December 18, 2024.","Record date for stockholders entitled to vote is October 31, 2024.","Stockholder proposals for proxy inclusion due by October 18, 2024, under Rule 14a-8.","Deadline for other business nominations and universal proxy rule compliance is also October 18, 2024.","Meeting date changed by more than 30 days from 2023 annual meeting anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207998,"accession_number":"0001493152-24-031477","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q2 2024 net loss widens to $5.8M; cash runway extended to Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $5.8M ($1.59/sh) from $3.8M ($1.04) a year ago; revenue fell to $1.6M from $1.8M.","Cash and equivalents $12.4M plus $1.4M restricted cash released; projected cash runway into Q4 2026 after MannKind transactions.","Recorded $2.6M loss on disposal group for assets transferred to MannKind in connection with iSPERSE technology validation.","Halted Phase 2b enrollment for PUR1900 with Cipla; wind down by Q3 2024; no further development funding, 2% royalty on future ex-US sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":7437000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207997,"accession_number":"0001493152-24-028507","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Teofilo Raad departs Pulmatrix; Peter Ludlum appointed Interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Teofilo Raad separated as CEO and Board member effective July 19, 2024; severance includes $567,294 salary, $156,310 prorated bonus, $283,647 separation bonus.","Peter Ludlum appointed Interim CEO effective July 20, 2024; also continues as Interim CFO; compensated at $700/hour via Danforth Advisors.","Ludlum eligible for retention bonuses totaling $50,000 ($30,000 upfront, $20,000 after annual meeting).","Raad's departure is not due to any disagreement regarding company operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225526,"accession_number":"0001493152-24-021732","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Pulmatrix cross-licenses iSPERSE with MannKind; transfers Bedford R&D facility to extend cash runway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pulmatrix grants MannKind exclusive iSPERSE licenses for clofazimine, NTM lung disease, insulin; non-exclusive for endocrine, ILD.","MannKind grants Pulmatrix exclusive Cricket device license for PUR3100 (DHE/migraine); non-exclusive for neurological disease.","MannKind assumes Pulmatrix's Bedford R&D facility lease and equipment; expected close July 2024.","CEO: transaction validates iSPERSE technology and extends cash runway into 2026.","MannKind to provide development services under MSA and may hire some Pulmatrix R&D staff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225525,"accession_number":"0001493152-24-019558","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulmatrix Phase 1 data for inhaled DHE (PUR3100) published: rapid absorption, better tolerability vs IV DHE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.","Lower incidence of nausea (21% vs 86%), vomiting (0% vs 29%), and headache (16% vs 57%) compared to IV DHE.","Data published in Headache: The Journal of Head and Face Pain; FDA allowed Phase 2 study to proceed.","Company seeking financing or partnership to advance PUR3100 into Phase 2 for acute migraine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225524,"accession_number":"0001493152-24-018576","cik":1574235,"company_name":"Pulmatrix, Inc.","ticker":"PULM","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulmatrix Q1 rev $5.9M, net income $0.8M; PUR1900 study wind down, cash runway into Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.9M (up $4.4M YoY) due to Cipla contract modification catch-up.","Net income $0.8M vs net loss $4.4M in prior year.","Cash $16.3M; expects cash runway into Q1 2026.","PUR1900 Phase 2b stopped (no safety concern); Pulmatrix bears no further dev cost, gets 2% royalty on ex-US sales.","PUR3100 Phase 2-ready; seeking partnership for Phase 2 study."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":5885000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5149721.227941177,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}